TC
XLRN

TFS Capital’s Acceleron Pharma XLRN Stock Holding History

TFS Capital’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-41,944
Closed -$1.52M – 942
2016
Q3 		$1.52M Sell
41,944
-15,204
-27% -$504K 0.36% 90
2016
Q2 		$1.94M Sell
57,148
-34,795
-38% -$1.13M 0.36% 18
2016
Q1 		$2.43M Sell
91,943
-18,858
-17% -$548K 0.35% 21
2015
Q4 		$5.4M Buy
110,801
+19,844
+22% +$714K 0.58% 24
2015
Q3 		$2.27M Sell
90,957
-27,771
-23% -$835K 0.22% 129
2015
Q2 		$3.76M Buy
118,728
+96,388
+431% +$3.11M 0.37% 54
2015
Q1 		$850K Buy
+22,340
New +$888K 0.08% 398
2014
Q3 		– Sell
-10,397
Closed -$353K – 1283
2014
Q2 		$353K Sell
10,397
-5,455
-34% -$182K 0.03% 778
2014
Q1 		$547K Buy
15,852
+7,703
+95% +$348K 0.04% 695
2013
Q4 		$323K Buy
+8,149
New +$197K 0.02% 1053

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

TFS Capital's XLRN Position: Q4 2016 in Review

TFS Capital sold out of Acceleron Pharma (XLRN) in Q4 2016, closing a stake of 41,944 shares — an estimated $1.52M sold.

TFS Capital first reported a position in XLRN in Q4 2013 and held it in 10 quarters. The position peaked at $5.4M in Q4 2015. 146 funds tracked by Wall St. Rank hold XLRN as of Q4 2016.

  • TFS Capital reported no remaining Acceleron Pharma position as of Q4 2016 after selling out during the quarter.
  • TFS Capital sold 41,944 Acceleron Pharma shares in Q4 2016, an estimated $1.52M.
  • TFS Capital first reported a position in Acceleron Pharma in Q4 2013 and held it in 10 quarters.
  • TFS Capital's Acceleron Pharma position peaked at $5.4M in Q4 2015.
  • 146 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2016.

Based on TFS Capital's 13F filing for Q4 2016, filed 20 Jan 2017.